Patents by Inventor Michael S. C. Fung
Michael S. C. Fung has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 8911735Abstract: The invention relates to C2a inhibitors, which bind to C2a and block the functional activity of C2a in complement activation. The inhibitors include antibody molecules, as well as homologs, analogs and modified or derived forms thereof, including immunoglobulin fragments like Fab, F(ab?)2 and Fv, small molecules, including peptides, oligonucleotides, peptidomimetics and organic compounds. A monoclonal antibody, which bound to C2a and blocked its ability to activate complement was generated and designated 175-62. The hybridoma producing this antibody was deposited at the American Type Culture Collection, 10801 University Blvd., Manassas, Va. 20110-2209, under Accession Number PTA-1553.Type: GrantFiled: June 15, 2012Date of Patent: December 16, 2014Assignee: Genentech, Inc.Inventors: Michael S. C. Fung, Cecily R. Y. Sun, William N. C. Sun
-
Patent number: 8383802Abstract: The invention relates to factor D inhibitors, which bind to factor D and block the functional activity of factor D in complement activation. The inhibitors include antibody molecules, as well as homologues, analogues and modified or derived forms thereof, including immunoglobulin fragments like Fab, F(ab?)2 and Fv, small molecules, including peptides, oligonucleotides, peptidomimetics and organic compounds. A monoclonal antibody which bound to factor D and blocked its ability to activate complement was generated and designated 166-32. The hybridoma producing this antibody was deposited at the American Type Culture Collection, 10801 University Blvd., Manassas, Va. 20110-2209, under Accession Number HB-12476.Type: GrantFiled: July 2, 2012Date of Patent: February 26, 2013Assignee: Genentech, Inc.Inventors: Michael S. C. Fung, William N. C. Sun, Cecily R. Y. Sun
-
Publication number: 20120322975Abstract: The invention relates to factor D inhibitors, which bind to factor D and block the functional activity of factor D in complement activation. The inhibitors include antibody molecules, as well as homologues, analogues and modified or derived forms thereof, including immunoglobulin fragments like Fab, F(ab?)2 and Fv, small molecules, including peptides, oligonucleotides, peptidomimetics and organic compounds. A monoclonal antibody which bound to factor D and blocked its ability to activate complement was generated and designated 166-32. The hybridoma producing this antibody was deposited at the American Type Culture Collection, 10801 University Blvd., Manassas, Va. 20110-2209, under Accession Number HB-12476.Type: ApplicationFiled: July 2, 2012Publication date: December 20, 2012Applicant: Genentech, Inc.Inventors: Michael S. C. Fung, William N.C. Sun, Cecily R. Y. Sun
-
Publication number: 20120251549Abstract: The invention relates to C2a inhibitors, which bind to C2a and block the functional activity of C2a in complement activation. The inhibitors include antibody molecules, as well as homologues, analogues and modified or derived forms thereof, including immunoglobulin fragments like Fab, F(ab?)2 and Fv, small molecules, including peptides, oligonucleotides, peptidomimetics and organic compounds. A monoclonal antibody, which bound to C2a and blocked its ability to activate complement was generated and designated 175-62. The hybridoma producing this antibody was deposited at the American Type Culture Collection, 10801 University Blvd., Manassas, Va. 20110-2209, under Accession Number PTA-1553.Type: ApplicationFiled: June 15, 2012Publication date: October 4, 2012Applicant: Genentech, Inc.Inventors: MICHAEL S.C. FUNG, Cecily R.Y. Sun, William N.C. Sun
-
Patent number: 8236317Abstract: The invention relates to factor D inhibitors, which bind to factor D and block the functional activity of factor D in complement activation. The inhibitors include antibody molecules, as well as homologues, analogues and modified or derived forms thereof, including immunoglobulin fragments like Fab, F(ab?)2 and Fv, small molecules, including peptides, oligonucleotides, peptidomimetics and organic compounds. A monoclonal antibody which bound to factor D and blocked its ability to activate complement was generated and designated 166-32. The hybridoma producing this antibody was deposited at the American Type Culture Collection, 10801 University Blvd., Manassas, Va. 20110-2209, under Accession Number HB-12476.Type: GrantFiled: January 17, 2012Date of Patent: August 7, 2012Assignee: Genentech, Inc.Inventors: Michael S. C. Fung, William N. C. Sun, Cecily R. Y. Sun
-
Patent number: 8221756Abstract: The invention relates to C2a inhibitors, which bind to C2a and block the functional activity of C2a in complement activation. The inhibitors include antibody molecules, as well as homologues, analogues and modified or derived forms thereof, including immunoglobulin fragments like Fab, F(ab?)2 and Fv, small molecules, including peptides, oligonucleotides, peptidomimetics and organic compounds. A monoclonal antibody, which bound to C2a and blocked its ability to activate complement was generated and designated 175-62. The hybridoma producing this antibody was deposited at the American Type Culture Collection, 10801 University Blvd., Manassas, Va. 20110-2209, under Accession Number PTA-1553.Type: GrantFiled: March 11, 2011Date of Patent: July 17, 2012Assignee: Genentech, Inc.Inventors: Michael S. C. Fung, Cecily R. Y. Sun, William N. C. Sun
-
Publication number: 20120141480Abstract: The invention relates to factor D inhibitors, which bind to factor D and block the functional activity of factor D in complement activation. The inhibitors include antibody molecules, as well as homologues, analogues and modified or derived forms thereof, including immunoglobulin fragments like Fab, F(ab?)2 and Fv, small molecules, including peptides, oligonucleotides, peptidomimetics and organic compounds. A monoclonal antibody which bound to factor D and blocked its ability to activate complement was generated and designated 166-32. The hybridoma producing this antibody was deposited at the American Type Culture Collection, 10801 University Blvd., Manassas, Va. 20110-2209, under Accession Number HB-12476.Type: ApplicationFiled: January 17, 2012Publication date: June 7, 2012Applicant: Genentech Inc.Inventors: Michael S.C. Fung, William N.C. Sun, Cecily R.Y. Sun
-
Patent number: 8124090Abstract: The invention relates to factor D inhibitors, which bind to factor D and block the functional activity of factor D in complement activation. The inhibitors include antibody molecules, as well as homologues, analogues and modified or derived forms thereof, including immunoglobulin fragments like Fab, F(ab?)2 and Fv, small molecules, including peptides, oligonucleotides, peptidomimetics and organic compounds. A monoclonal antibody which bound to factor D and blocked its ability to activate complement was generated and designated 166-32. The hybridoma producing this antibody was deposited at the American Type Culture Collection, 10801 University Blvd., Manassas, Va. 20110-2209, under Accession Number HB-12476.Type: GrantFiled: April 6, 2011Date of Patent: February 28, 2012Assignee: Genentech Inc.Inventors: Michael S. C. Fung, William N. C. Sun, Cecily R. Y. Sun
-
Publication number: 20110195069Abstract: The invention relates to factor D inhibitors, which bind to factor D and block the functional activity of factor D in complement activation. The inhibitors include antibody molecules, as well as homologues, analogues and modified or derived forms thereof, including immunoglobulin fragments like Fab, F(ab?)2 and Fv, small molecules, including peptides, oligonucleotides, peptidomimetics and organic compounds. A monoclonal antibody which bound to factor D and blocked its ability to activate complement was generated and designated 166-32. The hybridoma producing this antibody was deposited at the American Type Culture Collection, 10801 University Blvd., Manassas, Va. 20110-2209, under Accession Number HB-12476.Type: ApplicationFiled: April 6, 2011Publication date: August 11, 2011Inventors: Michael S.C. Fung, William N.C. Sun, Cecily R. Y. Sun
-
Publication number: 20110165169Abstract: The invention relates to C2a inhibitors, which bind to C2a and block the functional activity of C2a in complement activation. The inhibitors include antibody molecules, as well as homologues, analogues and modified or derived forms thereof, including immunoglobulin fragments like Fab, F(ab?)2 and Fv, small molecules, including peptides, oligonucleotides, peptidomimetics and organic compounds. A monoclonal antibody, which bound to C2a and blocked its ability to activate complement was generated and designated 175-62. The hybridoma producing this antibody was deposited at the American Type Culture Collection, 10801 University Blvd., Manassas, Va. 20110-2209, under Accession Number PTA-1553.Type: ApplicationFiled: March 11, 2011Publication date: July 7, 2011Inventors: Michael S.C. Fung, Cecily R. Y. Sun, William N.C. Sun
-
Patent number: 7943135Abstract: The invention relates to factor D inhibitors, which bind to factor D and block the functional activity of factor D in complement activation. The inhibitors include antibody molecules, as well as homologues, analogues and modified or derived forms thereof, including immunoglobulin fragments like Fab, F(ab?)2 and Fv, small molecules, including peptides, oligonucleotides, peptidomimetics and organic compounds. A monoclonal antibody which bound to factor D and blocked its ability to activate complement was generated and designated 166-32. The hybridoma producing this antibody was deposited at the American Type Culture Collection, 10801 University Blvd., Manassas, Va. 20110-2209, under Accession Number HB-12476.Type: GrantFiled: June 29, 2006Date of Patent: May 17, 2011Assignee: Genentech, Inc.Inventors: Michael S. C. Fung, William N. C. Sun, Cecily R. Y. Sun
-
Patent number: 7927592Abstract: The invention relates to C2a inhibitors, which bind to C2a and block the functional activity of C2a in complement activation. The inhibitors include antibody molecules, as well as homologues, analogues and modified or derived forms thereof, including immunoglobulin fragments like Fab, F(ab?)2 and Fv,b small molecules, including peptides, oligonucleotides, peptidomimetics and organic compounds. A monoclonal antibody, which bound to C2a and blocked its ability to activate complement was generated and designated 175-62. The hybridoma producing this antibody was deposited at the American Type Culture Collection, 10801 University Blvd., Manassas, Va. 20110-2209, under Accession Number PTA-1553.Type: GrantFiled: May 24, 2005Date of Patent: April 19, 2011Assignee: Genentech, Inc.Inventor: Michael S C Fung
-
Patent number: 7439331Abstract: The invention relates to factor D inhibitors, which bind to factor D and block the functional activity of factor D in complement activation. The inhibitors include antibody molecules, as well as homologues, analogues and modified or derived forms thereof, including immunoglobulin fragments like Fab, F(ab?)2 and Fv, small molecules, including peptides, oligonucleotides, peptidomimetics and organic compounds. A monoclonal antibody which bound to factor D and blocked its ability to activate complement was generated and designated 166-32. The hybridoma producing this antibody was deposited at the American Type Culture Collection, 10801 University Blvd., Manassas, Va. 20110-2209, under Accession Number HB-12476.Type: GrantFiled: June 29, 2006Date of Patent: October 21, 2008Assignee: Genentech, Inc.Inventors: Michael S. C. Fung, William N. C. Sun, Cecily R. Y. Sun
-
Publication number: 20080193442Abstract: The invention relates to factor D inhibitors, which bind to factor D and block the functional activity of factor D in complement activation. The inhibitors include antibody molecules, as well as homologues, analogues and modified or derived forms thereof, including immunoglobulin fragments like Fab, F(ab?)2 and Fv, small molecules, including peptides, oligonucleotides, peptidomimetics and organic compounds. A monoclonal antibody which bound to factor D and blocked its ability to activate complement was generated and designated 166-32. The hybridoma producing this antibody was deposited at the American Type Culture Collection, 10801 University Blvd., Manassas, Va. 20110-2209, under Accession Number HB-12476.Type: ApplicationFiled: June 29, 2006Publication date: August 14, 2008Inventors: Michael S.C. Fung, William N.C. Sun, Cecily R.Y. Sun
-
Patent number: 7112327Abstract: The invention relates to factor D inhibitors, which bind to factor D and block the functional activity of factor D in complement activation. The inhibitors include antibody molecules, as well as homologues, analogues and modified or derived forms thereof, including immunoglobulin fragments like Fab, F(ab?)2 and Fv, small molecules, including peptides, oligonucleotides, peptidomimetics and organic compounds. A monoclonal antibody which bound to factor D and blocked its ability to activate complement was generated and designated 166-32. The hybridoma producing this antibody was deposited at the American Type Culture Collection, 10801 University Blvd., Manassas, Va. 20110-2209, under Accession Number HB-12476.Type: GrantFiled: May 27, 2005Date of Patent: September 26, 2006Assignee: Tanox, Inc.Inventors: Michael S. C. Fung, William N. C. Sun, Cecily R. Y. Sun
-
Patent number: 6998468Abstract: The invention relates to C2a inhibitors, which bind to C2a and block the functional activity of C2a in complement activation. The inhibitors include antibody molecules, as well as homologues, analogues and modified or derived forms thereof, including immunoglobulin fragments like Fab, F(ab?)2 and Fv, small molecules, including peptides, oligonucleotides, peptidomimetics and organic compounds. A monoclonal antibody, which bound to C2a and blocked its ability to activate complement was generated and designated 175-62. The hybridoma producing this antibody was deposited at the American Type Culture Collection, 10801 University Blvd., Manassas, Va. 20110-2209, under Accession Number PTA-1553.Type: GrantFiled: March 23, 2001Date of Patent: February 14, 2006Assignee: Tanox, Inc.Inventors: Michael S. C. Fung, Cecily R. Y. Sun, William N. C. Sun
-
Patent number: 6956107Abstract: The invention relates to factor D inhibitors, which bind to factor D and block the functional activity of factor D in complement activation. The inhibitors include antibody molecules, as well as homologues, analogues and modified or derived forms thereof, including immunoglobulin fragments like Fab, F(ab?)2 and Fv, small molecules, including peptides, oligonucleotides, peptidomimetics and organic compounds. A monoclonal antibody which bound to factor D and blocked its ability to activate complement was generated and designated 166-32. The hybridoma producing this antibody was deposited at the American Type Culture Collection, 10801 University Blvd., Manassas, Va. 20110-2209, under Accession Number HB-12476.Type: GrantFiled: March 29, 2001Date of Patent: October 18, 2005Assignee: Tanox, Inc.Inventors: Michael S. C. Fung, William N. C. Sun, Cecily R. Y. Sun
-
Publication number: 20040198961Abstract: The present invention includes Fc&egr; fragments conjugated with FC&ggr; fragments, for example, Fc&egr;1-Hinge-FcE2-FcE3-FcE4-FCy; Hinge-FcE2-FcE3-FcE4-Fcy; FC&egr;2-Fc&egr;3-Fc&egr;4-FC&ggr;; FC&egr;2-Fc&egr;3-Fc&ggr;; FC&egr;3-Fc&ggr;; and FC&egr;3-Fc&egr;4-FC&ggr;, or any derivative or peptide, which has equivalent immunological function. The Fc&ggr; fragment may be a fragment of any of the IgG subclasses (IgG1 I IgG2, IgG3, or IgG4), preferably IgG1 or IgG3, wherein the fragment binds Fc&ggr;RIIB. The present invention also includes compositions suitable for administering to a patient suffering from an allergic disease comprising the fusion protein construct in a pharmaceutical composition including, for example, an excipient, diluant, or carrier. This treatment may be combined with anti-IgE therapy or allergen immunotherapy.Type: ApplicationFiled: April 29, 2004Publication date: October 7, 2004Inventors: Ling-Ling An, Herren Wu, Michael S.C. Fung
-
Patent number: 6657050Abstract: Chimeral viral-neutralizing, particularly HIV-neutralizing, immunoglobulins made up of a non-human antigen binding region and a human constant region are described.Type: GrantFiled: February 5, 1993Date of Patent: December 2, 2003Assignee: Tanox, Inc.Inventors: Cecily R. Y. Sun, Bill N. C. Sun, Michael S. C. Fung, Tse Wen Chang, Nancy T. Chang
-
Patent number: 6534058Abstract: The invention relates to C5 inhibitors, which inhibit type II endothelial cell activation, wherein the inhibition is manifested by the suppression of E-selectin. These inhibitors are useful in treatment of delayed xenograft rejection or acute vascular rejection. The inhibitors include antibody molecules, as well as homologues, analogues and modified or derived forms thereof, including immunoglobulin fragments like Fab, F(ab′)2 and Fv, small molecules, including peptides, oligonucleotides, peptidomimetics and organic compounds. Examples of monoclonal antibodies, which bind to and inhibit C5, were generated and are designated MAb 137-76 and MAb 137-30.Type: GrantFiled: October 4, 2001Date of Patent: March 18, 2003Assignee: Tanox, Inc.Inventors: Michael S. C. Fung, Bill N. C. Sun, Cecily R. Y. Sun